Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2010

01-09-2010 | Review

Abnormal Breath Testing in IBS: A Meta-Analysis

Authors: Eric D. Shah, Robert J. Basseri, Kelly Chong, Mark Pimentel

Published in: Digestive Diseases and Sciences | Issue 9/2010

Login to get access

Abstract

Background

Recent evidence suggests a role for enteric bacteria in the development of symptoms in subjects with irritable bowel syndrome (IBS). The concept was initially based on the common finding of an abnormal lactulose breath test to suggest the presence of small intestinal bacterial overgrowth (SIBO). Despite successful antibiotic studies based on these findings, the premise of bacterial overgrowth was met with skepticism due to the perceived inaccuracies of breath testing in humans. In this study, we conduct a systematic review and meta-analysis of the studies using breath testing in IBS subjects with comparison to healthy controls.

Methods

A literature search was conducted to identify studies in which breath testing was conducted in subjects with IBS. Once abstract titles were identified, studies that examined breath testing in a case–control fashion were identified for paper review. After exclusion criteria were applied, the remaining papers were examined using meta-analysis, among which the prevalence of an abnormal breath test in IBS subjects was compared. Further analysis was conducted among studies with appropriate age- and sex-matched controls.

Results

Eleven studies met criteria for inclusion in the meta-analysis. Although heterogeneity was identified among studies on the basis of substrate used, lactulose was the most common substrate. In pooling the 11 studies, breath testing was more often abnormal among IBS subjects than health controls (OR = 4.46, 95% CI = 1.69–11.80). This was further evident in more appropriately designed age- and sex-matched studies (OR = 9.64, 95% CI = 4.26–21.82). The overall sensitivity and specificity for breath testing in separating IBS from healthy controls was 43.6 and 83.6%.

Conclusions

This study demonstrates that the breath test findings in IBS appear to be valid. While this meta-analysis does not suggest that the breath test findings imply SIBO, the abnormal fermentation timing and dynamics of the breath test findings support a role for abnormal intestinal bacterial distribution in IBS.
Literature
1.
go back to reference Drossman DA, senior ed; Corazziari E, Talley NJ, Thompson WG, Whitehead WE, The Rome II Multinational Working Teams, eds. Rome II: The Functional Gastrointestinal Disorders. 2nd edn. McLean, Va: Degnon Associates; 2000. Drossman DA, senior ed; Corazziari E, Talley NJ, Thompson WG, Whitehead WE, The Rome II Multinational Working Teams, eds. Rome II: The Functional Gastrointestinal Disorders. 2nd edn. McLean, Va: Degnon Associates; 2000.
2.
go back to reference Whitehead WE, Burnett CK, Cook EW III, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2248–2253.CrossRefPubMed Whitehead WE, Burnett CK, Cook EW III, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2248–2253.CrossRefPubMed
3.
go back to reference Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;11:654–660.CrossRef Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;11:654–660.CrossRef
4.
go back to reference Hungin AP, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Ailment Pharmacol Ther. 2003;17:643–650.CrossRef Hungin AP, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Ailment Pharmacol Ther. 2003;17:643–650.CrossRef
5.
go back to reference Wilson S, Roberts L, Roalfe A, et al. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 2004;54:495–502.PubMed Wilson S, Roberts L, Roalfe A, et al. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 2004;54:495–502.PubMed
6.
go back to reference Maxion-Bergemann S, Thielecke F, Abel F, et al. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006;24:21–37.CrossRefPubMed Maxion-Bergemann S, Thielecke F, Abel F, et al. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006;24:21–37.CrossRefPubMed
7.
go back to reference Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419.PubMed Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419.PubMed
8.
go back to reference Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med. 2006;145(8):557–563.PubMed Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med. 2006;145(8):557–563.PubMed
9.
go back to reference Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326–333.CrossRefPubMed Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326–333.CrossRefPubMed
10.
go back to reference Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506.CrossRefPubMed Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506.CrossRefPubMed
11.
go back to reference Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–808.CrossRefPubMed Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–808.CrossRefPubMed
13.
go back to reference Vanner S. The small intestinal bacterial overgrowth, irritable bowel syndrome hypothesis: implications for treatment. Gut. 2008;57:1315–1321.CrossRefPubMed Vanner S. The small intestinal bacterial overgrowth, irritable bowel syndrome hypothesis: implications for treatment. Gut. 2008;57:1315–1321.CrossRefPubMed
14.
go back to reference Khoshini R, Dai SC, Lezcano S, et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53:1443–1454.CrossRefPubMed Khoshini R, Dai SC, Lezcano S, et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53:1443–1454.CrossRefPubMed
15.
go back to reference Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49:7–18.CrossRefPubMed Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49:7–18.CrossRefPubMed
16.
go back to reference Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566–1570.CrossRefPubMed Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566–1570.CrossRefPubMed
17.
go back to reference DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
18.
go back to reference Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statist Med. 2004;23:1351–1375.CrossRef Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statist Med. 2004;23:1351–1375.CrossRef
19.
go back to reference Higgens JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23:1663–1682.CrossRef Higgens JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23:1663–1682.CrossRef
20.
go back to reference Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analysis of controlled clinical trials with binary endpoints. Stat Med. 2006;25:3443–3457.CrossRefPubMed Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analysis of controlled clinical trials with binary endpoints. Stat Med. 2006;25:3443–3457.CrossRefPubMed
21.
go back to reference Galatola G, Grosso M, Barlotta A, et al. Diagnosis of bacterial contamination of the small intestine using the 1 g [14C] xylose breath test in various gastrointestinal diseases. Minerva Gastroenterol Dietol. 1991;37:169–175.PubMed Galatola G, Grosso M, Barlotta A, et al. Diagnosis of bacterial contamination of the small intestine using the 1 g [14C] xylose breath test in various gastrointestinal diseases. Minerva Gastroenterol Dietol. 1991;37:169–175.PubMed
22.
go back to reference Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450–452.CrossRefPubMed Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450–452.CrossRefPubMed
23.
go back to reference Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157–1160.CrossRefPubMed Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157–1160.CrossRefPubMed
24.
go back to reference Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol. 2008;103:958–963.CrossRefPubMed Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol. 2008;103:958–963.CrossRefPubMed
25.
go back to reference Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil. 2008;20:998–1008.CrossRefPubMed Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil. 2008;20:998–1008.CrossRefPubMed
26.
go back to reference Rana SV, Sinha SK, Sikander A, et al. Study of small intestinal bacterial overgrowth in North Indian patients with irritable bowel syndrome: a case control study. Trop Gastroenterol. 2008;29:23–25.PubMed Rana SV, Sinha SK, Sikander A, et al. Study of small intestinal bacterial overgrowth in North Indian patients with irritable bowel syndrome: a case control study. Trop Gastroenterol. 2008;29:23–25.PubMed
27.
go back to reference Skoog SM, Bharucha AE, Zinsmeister AR. Comparison of breath testing with fructose and high fructose corn syrups in health and IBS. Neurogastroenterol Motil. 2008;20:505–511.CrossRefPubMed Skoog SM, Bharucha AE, Zinsmeister AR. Comparison of breath testing with fructose and high fructose corn syrups in health and IBS. Neurogastroenterol Motil. 2008;20:505–511.CrossRefPubMed
28.
go back to reference Parodi A, Dulbecco P, Savarino E, et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol. 2009;43:962–966.CrossRefPubMed Parodi A, Dulbecco P, Savarino E, et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol. 2009;43:962–966.CrossRefPubMed
29.
go back to reference Scarpellini E, Giorgio V, Gabrielli M, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr. 2009;155:416–420.CrossRefPubMed Scarpellini E, Giorgio V, Gabrielli M, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr. 2009;155:416–420.CrossRefPubMed
30.
go back to reference Collins BS, Lin HC. Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. Dig Dis Sci. 2010;55:124–130.CrossRefPubMed Collins BS, Lin HC. Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. Dig Dis Sci. 2010;55:124–130.CrossRefPubMed
31.
go back to reference Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103:2972–2976.CrossRefPubMed Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103:2972–2976.CrossRefPubMed
32.
go back to reference Law D, Pimentel M. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. Dig Dis Sci (in press) (Epub ahead of print). Law D, Pimentel M. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. Dig Dis Sci (in press) (Epub ahead of print).
33.
go back to reference Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279–1286.CrossRefPubMed Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279–1286.CrossRefPubMed
34.
go back to reference Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharm Ther. 2009;29:S1–S49. Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharm Ther. 2009;29:S1–S49.
35.
go back to reference Bond JH, Engel RR, Levitt MD. Factors influencing pulmonary methane excretion in man. An indirect method of studying the in situ metabolism of the methane-producing colonic bacteria. J Exp Med. 1971;133:572–588.CrossRefPubMed Bond JH, Engel RR, Levitt MD. Factors influencing pulmonary methane excretion in man. An indirect method of studying the in situ metabolism of the methane-producing colonic bacteria. J Exp Med. 1971;133:572–588.CrossRefPubMed
36.
go back to reference Pimentel M, Mayer AG, Park S, et al. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003;48:86–92.CrossRefPubMed Pimentel M, Mayer AG, Park S, et al. Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci. 2003;48:86–92.CrossRefPubMed
37.
go back to reference Hwang L, Low K, Khoshini R, et al. Evaluating breath methane as a diagnostic test for constipation predominant IBS. Dig Dis Sci. 2010;55:398–403.CrossRefPubMed Hwang L, Low K, Khoshini R, et al. Evaluating breath methane as a diagnostic test for constipation predominant IBS. Dig Dis Sci. 2010;55:398–403.CrossRefPubMed
38.
go back to reference Pimentel M, Chow EJ, Park S, Kong Y. Neomycin improves constipation in IBS in a fashion that is dependent on the presence of methane gas: sub-analysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297–1301.CrossRefPubMed Pimentel M, Chow EJ, Park S, Kong Y. Neomycin improves constipation in IBS in a fashion that is dependent on the presence of methane gas: sub-analysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297–1301.CrossRefPubMed
Metadata
Title
Abnormal Breath Testing in IBS: A Meta-Analysis
Authors
Eric D. Shah
Robert J. Basseri
Kelly Chong
Mark Pimentel
Publication date
01-09-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1276-4

Other articles of this Issue 9/2010

Digestive Diseases and Sciences 9/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.